Emergent BioSolutions (NYSE:EBS) Upgraded at StockNews.com

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS) from a hold rating to a buy rating in a research report released on Thursday morning.

A number of other research firms have also weighed in on EBS. Benchmark increased their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS opened at $8.48 on Thursday. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The company has a market cap of $459.45 million, a PE ratio of -2.07 and a beta of 1.59. The company’s 50 day moving average is $9.35 and its 200 day moving average is $8.70.

Institutional Investors Weigh In On Emergent BioSolutions

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. CWM LLC boosted its holdings in Emergent BioSolutions by 32,706.7% during the second quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 4,906 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Emergent BioSolutions during the second quarter worth about $41,000. Price T Rowe Associates Inc. MD raised its position in shares of Emergent BioSolutions by 22.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 4,409 shares during the last quarter. Verus Capital Partners LLC purchased a new position in Emergent BioSolutions in the 2nd quarter valued at about $68,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in Emergent BioSolutions during the 2nd quarter worth approximately $93,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.